NDAORALTABLET
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEMLIDY (tenofovir alafenamide) is an oral nucleotide reverse transcriptase inhibitor approved in 2016 for chronic hepatitis B virus (HBV) infection. It is a small-molecule prodrug that converts to tenofovir in cells, inhibiting HBV reverse transcriptase with improved renal and bone safety compared to earlier tenofovir formulations.
$0.188BPart D
PeakStable
6.7 years to LOEProduct is at peak commercial maturity with strong, sustained Medicare Part D utilization; brand and field teams are likely at full capacity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)
Started May 2026
16 enrolled
Healthy
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Started Mar 2026
200 enrolled
HIV -1 InfectionHIV (Human Immunodeficiency Virus)HIV+1 more
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
Started Aug 2025
16 enrolled
HIV-1-infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
Started Oct 2024
609 enrolled
HIV-1-infection
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
Started Mar 2024
26 enrolled
HIV I InfectionCardiovascular Risk FactorLipid Metabolism Disorders
Worked on VEMLIDY at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.